Regenerative Medicine — What Happened & What’s Next, Part 3: Stem Cells

Stem Cells - Why use them? Why are there so many different kinds? Where are we now?

Go to the profile of Rhonda Wallen
Nov 27, 2016

This article, the third installment in the series, will provide you with enough background to be dangerous and will help those new to this regenerative medicine modality understand the promise and challenges of both allogeneic and autologous approaches. What Happened & What's Next - Stem Cells

Go to the profile of Rhonda Wallen

Rhonda Wallen

Head, Strategic Growth & Alliances, Terumo BCT

Ms. Wallen is an entrepreneur and former venture capitalist who advises young companies on matters of financing, strategy and business development and provides diligence and strategic advice for angel and investment groups as they evaluate potential investments in life science opportunities. Trained in molecular biology at Stanford, Ms. Wallen began her career studying growth factors and their impact on cell differentiation. Following graduate school she delved into regenerative medicine during her leadership of drug delivery and biomaterials licensing and collaborations at Bayer and then Guidant (Boston Scientific). As a venture investor, Ms. Wallen performed in depth evaluation of dozens of deals in biotech, medtech, and diagnostics and invested over $10M of capital which has generated returns to investors. She has co-founded two therapeutic-focused oncology companies, raised capital, and negotiated and executed numerous strategic partnership, licensing and R&D agreements.

No comments yet.